Low-grade oligodendroglioma responds to chemotherapy Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Brain Neoplasms
  • Oligodendroglioma

abstract

  • We administered chemotherapy in standard and intensified formulations of procarbazine, lomustine (CCNU), and vincristine to nine symptomatic patients with low-grade oligodendroglioma. Eight patients were treated with chemotherapy at presentation and one was treated for a recurrence after radiotherapy had failed. All patients improved by clinical or MRI criteria, or both. No patient deteriorated while in therapy and the responses were sustained without radiotherapy for a median of 35 months (range, 22-45) in all surviving patients treated at presentation. Chemotherapy was well tolerated; all patients developed myelosuppression, but only those receiving the intensified regimen required dose reduction or premature discontinuation of treatment. As with recurrent and anaplastic oligodendroglioma, low-grade oligodendroglioma responds to chemotherapy.

publication date

  • January 1996

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8559376

Additional Document Info

start page

  • 203

end page

  • 7

volume

  • 46

number

  • 1